A single-centre, open-label randomised trial of empagliflozin 10 mg in 70 patients with type 2 diabetes and HFpEF found improved 6-minute walk distance and diastolic reserve markers. PICO summary and expert commentary.
Browsing: SGLT2 Inhibitors
Design paper for the DAPA ACT HF-TIMI 68 trial testing in-hospital dapagliflozin versus placebo in 2,401 patients with acute heart failure; no efficacy results are reported. PICO summary and expert commentary.
A biomarker substudy of the EMPEROR program shows empagliflozin activates the erythropoietin-erythroferrone-hepcidin axis and raises haemoglobin in heart failure. PICO summary and expert commentary.
A 24-week open-label randomised trial testing pioglitazone plus empagliflozin versus monotherapy for fatty liver in type 2 diabetes. PICO summary and expert commentary.
The PARTNER study is a published trial protocol, not a results paper: it describes the rationale and design of a randomised crossover trial of dapagliflozin plus continuous ketone monitoring in type 1 diabetes, with no outcomes yet reported. PICO summary and expert commentary.
A post-hoc sub-analysis of the open-label PROCEED RCT found ipragliflozin did not improve LV diastolic function overall, with only exploratory subgroup signals. PICO summary and expert commentary.
A small mechanistic RCT (n=34) found ertugliflozin did not increase proximal tubular natriuresis (the primary outcome) but did reduce fluid volume and blood pressure by week 12. PICO summary and expert commentary.
A small open-label randomised trial comparing dapagliflozin with insulin glargine as a fourth agent for glycaemic variability in type 2 diabetes inadequately controlled on triple therapy. PICO summary and expert commentary.
A decentralized n-of-1 crossover trial found dapagliflozin lowered the urine albumin-to-creatinine ratio by 15.1% versus placebo over 1-week periods in 20 adults with type 2 diabetes, while demonstrating reliable remote sampling. PICO summary and expert commentary.
An open-label trial found that pioglitazone/metformin plus dapagliflozin did not beat basal insulin/metformin on its primary glycaemic endpoint, with secondary metabolic signals favouring the oral regimen. PICO summary and expert commentary.